New drug GenSci155 tested in healthy people for first time
NCT ID NCT07638800
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage study tests the safety and tolerability of a new drug called GenSci155 in 68 healthy adults aged 18 to 60. Participants receive either the drug or a placebo by IV, and researchers monitor side effects and how the drug moves through the body. Since this is a Phase 1 trial in healthy volunteers, it does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT TRIAL PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenSci155 injection
What could go wrong
This is a very early Phase 1 study in healthy people, so it cannot show whether GenSci155 works for any disease. The main goal is safety, not effectiveness.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.